Linamide10 mg

Linamide is an oral immunomodulatory antineoplastic agent (a thalidomide analog) used in the treatment of certain blood cancers. Its established, FDA-approved indications include:

• Multiple myeloma: In combination with dexamethasone for adults with multiple myeloma; also approved as single-agent maintenance therapy following autologous hematopoietic stem cell transplantation (HSCT).
• Myelodysplastic syndromes (MDS): For transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q (del5q) cytogenetic abnormality, with or without additional cytogenetic abnormalities.
• Mantle cell lymphoma (MCL): For relapsed or refractory mantle cell lymphoma that has progressed after two prior therapies, one of which included a proteasome inhibitor.
• Follicular lymphoma (FL) and marginal zone lymphoma (MZL): In combination with rituximab, for previously treated follicular lymphoma or marginal zone lymphoma (adjunct/combination-therapy use; not for use as monotherapy in this setting).

Linamide must only be prescribed and monitored by a physician experienced in the use of antineoplastic/immunomodulatory therapy, under a controlled distribution and risk-management program.

Each capsule of Lenalidomide contains Lenalidomide as the active ingredient, available in strengths such as 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, together with pharmaceutically inactive excipients.

Linamide is a synthetic immunomodulatory and antiangiogenic agent structurally related to thalidomide. It is used in oncology/hematology for selected blood cancers under specialist supervision. Linamide acts by modulating the immune system, inhibiting angiogenesis, and directly promoting death of malignant cells, and it carries boxed warnings for severe birth defects, blood cell toxicity, and blood clot risk.

Linamide belongs to the class of immunomodulatory antineoplastic agents (thalidomide analogs / IMiDs), used in the management of multiple myeloma and selected lymphoid and myeloid malignancies.

Lenalidomide is an immunomodulatory drug (IMiD) that binds cereblon, a component of an E3 ubiquitin ligase complex, altering the ubiquitination and degradation of specific target proteins (including the transcription factors IKZF1 and IKZF3). This produces direct anti-tumor and anti-proliferative effects on malignant hematopoietic cells, enhances T-cell and NK-cell mediated immunity, and inhibits angiogenesis. Lenalidomide also modulates production of pro-inflammatory and anti-inflammatory cytokines such as TNF-alpha.

Linamide capsules should be swallowed whole with a full glass of water, at approximately the same time each day, with or without food. Do not open, crush, break, or chew the capsule. Pregnant women should avoid direct contact with the capsule contents.

Linamide has the following clinically significant drug interactions:

• Digoxin: Concomitant use with Linamide increases digoxin plasma concentration (Cmax and AUC); digoxin levels should be monitored periodically during treatment.
• Erythropoiesis-stimulating agents (e.g., erythropoietin): Increase the risk of thrombotic events when combined with Linamide; use with caution.
• Estrogen-containing therapies (e.g., hormonal contraceptives, hormone replacement therapy): May further increase the risk of thrombosis in patients taking Linamide, particularly with dexamethasone; alternative contraception is generally advised (see Precautions and Warnings).
• Dexamethasone/corticosteroids: Combination substantially increases the risk of venous and arterial thromboembolism (see Precautions and Warnings for thromboprophylaxis guidance).
• Warfarin and other agents affecting coagulation: Close monitoring is advised given the additive thrombotic/bleeding risk profile.

Common side effects of Linamide vary somewhat by indication but commonly include:

• Neutropenia, thrombocytopenia, anemia, and leukopenia (may be severe; see Precautions and Warnings)
• Diarrhea, constipation, nausea
• Fatigue, weakness, insomnia
• Muscle cramps, back pain
• Peripheral edema, rash, pruritus (itching)
• Fever, cough, shortness of breath

Serious but less common effects include severe blood clots (deep vein thrombosis, pulmonary embolism), heart attack or stroke, severe skin reactions, tumor lysis syndrome, and second primary malignancies. Report any unusual bruising/bleeding, leg swelling, chest pain, shortness of breath, or severe rash to a physician immediately.

Linamide is contraindicated in pregnancy due to a high risk of severe, life-threatening birth defects and fetal loss (embryo-fetal toxicity), similar to its parent compound thalidomide. Females of reproductive potential must have a negative pregnancy test before starting Linamide and must use effective contraception (or complete abstinence) during and for a defined period after treatment, under a physician-supervised risk-management program. Males taking Linamide must use condoms during sexual contact with women who are or could become pregnant, as the drug is present in semen. Sperm and blood donation are prohibited during treatment and for a period afterward. Linamide or its effects may pass into breast milk, and breastfeeding is not recommended during treatment; a physician should be consulted regarding infant feeding.

Linamide carries boxed warnings and requires close specialist monitoring:

• Embryo-fetal toxicity: Never use during pregnancy; strict contraception/risk-management program required (see Pregnancy and Lactation).
• Hematologic toxicity: Significant neutropenia and thrombocytopenia are common; complete blood counts must be monitored regularly, with dose interruption or reduction as needed.
• Venous and arterial thromboembolism: Increased risk of deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke, especially when combined with dexamethasone; thromboprophylaxis is often recommended based on individual risk factors.
• Second primary malignancies: Increased risk observed with long-term use, particularly in multiple myeloma maintenance therapy.
• Hepatotoxicity and severe skin reactions: Liver function should be monitored; discontinue if severe rash, Stevens-Johnson syndrome, or toxic epidermal necrolysis develops.
• Tumor lysis syndrome and allergic reactions: Monitor closely, especially in patients with high tumor burden.

Linamide is available only through a restricted distribution program and must be taken exactly as prescribed by the treating specialist; do not share this medicine with anyone else.

There is limited clinical experience with Linamide overdose. Suspected overdose may worsen known adverse effects, particularly severe bone marrow suppression (neutropenia, thrombocytopenia). If an overdose of Linamide is suspected, seek immediate medical attention or contact emergency services/poison control; supportive care and close monitoring of blood counts should be provided by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Keep Linamide in its original container and do not transfer it to another container.

Renal impairment: Dose adjustment of Linamide is required based on creatinine clearance (see Dosage and Administration), as the drug is primarily renally excreted.

Hepatic impairment: Limited data are available; use with caution and physician supervision.

Elderly patients: May be more sensitive to adverse effects of Linamide, particularly renal function decline and thromboembolic events; dose selection should account for renal function.

Pediatric patients: Safety and effectiveness of Linamide have not been established in children (see Pediatric Uses).

Pregnant/reproductive-potential patients: See Pregnancy and Lactation and Contraindications.

Treatment duration with Linamide is determined by the treating specialist based on indication, response, and tolerability. In multiple myeloma, treatment is often continued until disease progression or unacceptable toxicity; in follicular/marginal zone lymphoma, treatment combined with rituximab is typically given for up to 12 cycles. Do not extend, shorten, or stop treatment with Linamide without physician guidance.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class of antineoplastic agents, a group of thalidomide analogs.

Lenalidomide binds to cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase complex, promoting the degradation of the transcription factors IKZF1 and IKZF3. This produces direct anti-tumor and anti-proliferative effects on malignant plasma cells and lymphoid/myeloid clones, stimulates T-cell and natural killer (NK) cell immune activity, and inhibits angiogenesis and pro-inflammatory cytokine production.

X

The safety and effectiveness of Linamide have not been established in pediatric patients. Linamide is not approved for use in children and should only be used in adults under specialist oncology/hematology supervision.